Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG005 with Gecacitinib and Chemotherapy in Advanced Solid Tumors
NCT07142837Phase 2Not yet recruiting
- Sponsor
- Zelgen
- Start
- Sep 2025
- Primary completion
- Oct 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nilvanstomig in solid tumor (advanced stage), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 1 more (2 arms), sponsored by Zelgen. Primary endpoints: Dose Limiting Toxicity at 28 days, Objective Response Rate at 2 years and 1 more. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
nilvanstomig
03
Conditions
solid tumor (advanced stage)gastric adenocarcinomagastroesophageal junction adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07142837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142837.